[HTML][HTML] Ecology and evolution of dormant metastasis
Genetic studies suggest that sequential dissemination from a primary metastasis, usually at
the bone, is a major route of metastatic progression in early, radically resected cancer …
the bone, is a major route of metastatic progression in early, radically resected cancer …
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Purpose: Enfortumab vedotin (EV) is an antibody–drug conjugate (ADC) targeting NECTIN4
(encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic …
(encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic …
[HTML][HTML] Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in establishing faithful pre-clinical cancer models
One of the major bottlenecks in advancing basic cancer research and developing novel
cancer therapies is the lack of in vitro pre-clinical models that faithfully recapitulate tumor …
cancer therapies is the lack of in vitro pre-clinical models that faithfully recapitulate tumor …
Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma
Background Characterization of the different genomic alterations (GAs) in urothelial
carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and …
carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and …
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1
Histone H2A lysine 119 (H2AK119Ub) is monoubiquitinated by Polycomb repressive
complex 1 and deubiquitinated by Polycomb repressive deubiquitinase complex (PR-DUB) …
complex 1 and deubiquitinated by Polycomb repressive deubiquitinase complex (PR-DUB) …
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Background Enfortumab vedotin (EV) is a novel antibody‐drug conjugate approved for
advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer …
advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer …
[HTML][HTML] Single-cell atlases link macrophages and CD8+ T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
Y Liang, Y Tan, B Guan, B Guo, M Xia, J Li, Y Shi… - Theranostics, 2022 - ncbi.nlm.nih.gov
Abstract Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the
management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to …
management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to …
KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer
H Qiu, V Makarov, JK Bolzenius, A Halstead, Y Parker… - Cancer research, 2023 - AACR
Disruption of KDM6A, a histone lysine demethylase, is one of the most common somatic
alternations in bladder cancer. Insights into how KDM6A mutations affect the epigenetic …
alternations in bladder cancer. Insights into how KDM6A mutations affect the epigenetic …
Precision oncology: current and future platforms for treatment selection
Genomic profiling of hundreds of cancer-associated genes is now a component of routine
cancer care. DNA sequencing can identify mutations, mutational signatures, and structural …
cancer care. DNA sequencing can identify mutations, mutational signatures, and structural …
[HTML][HTML] Transcriptomic profiling of upper tract urothelial carcinoma: bladder cancer consensus classification relevance, molecular heterogeneity, and differential …
J Fontugne, E Xylinas, C Krucker, V Dixon… - Modern Pathology, 2023 - Elsevier
Analyses of large transcriptomics data sets of muscle-invasive bladder cancer (MIBC) have
led to a consensus classification. Molecular subtypes of upper tract urothelial carcinomas …
led to a consensus classification. Molecular subtypes of upper tract urothelial carcinomas …